LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk is under pressure from investors ... than its blockbuster weight-loss injection Wegovy, but investors are worried whether it will be good ...

Novo Nordisk has an Earnings ESP of -1.42% and a Zacks Rank #4 (Sell) at present. You can see the complete list of today’s Zacks #1 Rank stocks here. Factors Shaping NVO’s Upcoming Results NVO ...

the controlling shareholder of Novo Nordisk, which makes the blockbuster obesity drug Wegovy and diabetes medication. Novo’s record profit from obesity drugs has given the Foundation a ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current best-selling drug in this area, Wegovy, to shame. Let's look deeper into these ...

Multiple reasons to invest Novo Nordisk faces at least two issues in the anti-obesity space. First, while this market is growing fast, it isn't expanding as quickly as many anticipated. Novo ...

Recently, the Centers for Medicare & Medicaid Services (CMS) included Novo Nordisk’s key GLP-1 drugs, Ozempic and Wegovy, in its list of 15 drugs for Medicare price negotiations. This announcement ...

(Image Credits: Pixabay) The United States Food and Drug Administration (USFDA) has approved Novo Nordisk’s Ozempic ... as its popular obesity treatment Wegovy. The USFDA’s approval makes ...

Novo Nordisk (NVO) said its popular diabetes drug ... for weight loss and is marketed for that indication under the name Wegovy. In 2020, Ozempic was granted additional approval to reduce the ...

Novo Nordisk said the Food and Drug Administration ... The FDA approved semaglutide for weight loss under the brand name Wegovy in 2021. The European Union's drug regulator has already thrown ...

When Novo Nordisk unveiled kidney outcomes data for ... franchise—covering both Ozempic and Rybelsus in diabetes and Wegovy in obesity—continues to thrive. Aside from raking in billions ...